1. Introduction {#Section1}
===============

Inflammation acts as the initial host defense against invasive pathogens and other inciting stimulus. It plays an important role in tissue repair and elimination of harmful pathogens. Although the inflammatory response is essential for host defense, it is very much a double-edged sword. Inappropriate inflammatory reaction or delay in the resolution of inflammation will damage adjacent normal cells in the tissue. Microbial infection is most commonly caused by bacteria and viruses, while sterile inflammation is triggered by sterile stimulus involving physical, chemical or metabolic noxiae such as burns, trauma, and dead cells [@B1], [@B2]. Similar to infection, the sterile inflammatory process also includes the recruitment of neutrophils, macrophages, and the production of proinflammatory cytokines and chemokines [@B3]. Accumulating evidence supports that various human diseases, including stroke, Alzheimer\'s disease, atherosclerosis, and many autoimmune diseases, are related to sterile inflammation. These diseases happen and evolve, at least in part, due to the improper resolution of inflammatory processes [@B4].

Molecular imaging can visualize, characterize, and measure the biological processes at the molecular and cellular levels in humans and other organisms [@B5]. Many imaging techniques are incorporated in the molecular imaging realm, including magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), optical imaging, ultrasound [@B6], and photoacoustic imaging [@B7]. Each technique has its own unique applications, advantages, and limitations. Compared with other imaging modalities, PET features high sensitivity and specificity. Therefore, PET has become one of the most frequently used molecular imaging techniques in the clinic. Besides, the hybridization of PET with CT and MR provides additional anatomical details to the lesions, allowing for both high sensitivity molecular and anatomical/functional imaging.

^18^F-FDG (2-deoxy-2-^18^F-fluoro-D-glucose) is the most extensively used PET imaging tracer and has been applied successfully in tumor detection, staging, and therapy evaluation, as well as in cardiovascular and neurological diseases [@B8]. In inflammatory diseases, ^18^F-FDG PET also has its value, particularly in atherosclerosis and some arthritis diseases [@B9], [@B10] **(Table [1](#T1){ref-type="table"})**. However, ^18^F-FDG PET imaging of inflammation tends to give false-positive results, especially in patients with cancer. Moreover, the high tracer accumulation in the heart and brain makes it difficult to detect inflammatory foci near those organs or tissues. Consequently, new imaging tracers and targets for more specific inflammation detection and therapy evaluation are under intensive investigation. PET imaging with these new tracers greatly improved our understanding of the mechanism of inflammation and increased the diagnostic specificity and accuracy of inflammatory foci. As summarized in Figure [1](#F1){ref-type="fig"}, various radiopharmaceuticals have been developed for PET imaging of inflammation, targeting different biomarkers from macrophages to angiogenesis. In this review, we will summarize these potential imaging targets and tracers for inflammation PET imaging, the applications of PET in major inflammatory diseases, and tumor associated inflammation imaging. The current attempt to differentiate inflammation from tumor using PET is also elaborated. A discussion of pathogen targeted PET imaging is beyond the scope of this review.

2. Biomarkers for inflammation imaging {#Section2}
======================================

After being triggered by various stimuli, the inflammation cascade begins with the release of various pro-inflammatory mediators including cytokines, chemokines, and leukotrienes by resident inflammatory and endothelial cells. Next, vascular permeability is increased with the infiltration of neutrophils and macrophages. In the late phase, the release of pro-resolving mediators causes apoptosis of inflammatory cells and leads to the termination of inflammation. All these key inflammatory mediators and specific features of dominant inflammatory cells are potential targets for either visualization or treatment of inflammatory disorders. In this section, we will cover the major biomarkers of inflammation and the corresponding probes for PET imaging, including the metabolic rate and membrane markers of inflammatory cells, cytokines, and vessels within inflamed foci, as well as some newly identified inflammation related targets.

2.1 Metabolic activity of inflammatory cells {#Section2.1}
--------------------------------------------

### 2.1.1 Glucose metabolism {#Section2.1.1}

High glucose metabolism and consequent high FDG accumulation are not unique phenomena for malignant cells. Benign processes including inflammatory disorders also show increased FDG uptake, which bring about false positiveness in tumor detection [@B27]. As the key indicators and core participants in inflammatory foci, infiltrating inflammatory cells utilize glucose at a much higher level than peripheral non-inflammatory cells. Therefore, the increased glucose metabolism of inflamed foci due to oxidative burst in the inflammatory cells become an important and most frequently used target in PET imaging of inflammation. CT or MRI is often combined with ^18^F-FDG PET to increase the diagnostic accuracy. Indeed, ^18^F-FDG has been used intensively in a great number of inflammatory diseases and therapy evaluations, part of which are summarized in **Table [1](#T1){ref-type="table"}**. For details of the applications of ^18^F-FDG in inflammation imaging, please refer to previously published review articles [@B28], [@B29].

### 2.1.2 Choline metabolism {#Section2.1.2}

Choline is an important precursor of phosphatidylcholine and sphingomyelin, two classes of phospholipids that are abundant in cell membranes. The phosphatidylcholine catabolism by many nucleated cells, mostly proliferative cells, serves as an imaging target both in cancers and in some inflammatory diseases. PET using radiolabeled choline has been used to image prostate cancer [@B30]-[@B33]. By targeting the macrophages and monocytes in inflammatory diseases, choline is also used to image atherosclerosis [@B34]-[@B36] and to evaluate necrosis after brain tumor radiation therapy [@B37]. Matter *et al.* found via *ex vivo* micro-autoradiography that ^18^F-choline had greater sensitivity in detecting atherosclerotic plaques than FDG (84% versus 64%) [@B34]. In a clinical setting with five patients, Bucerius *et al.* [@B36] demonstrated the feasibility of ^18^F-choline to image structural wall alteration in humans. A major advantage offered by ^18^F-choline imaging over ^18^F-FDG is the lack of ^18^F-choline uptake in the myocardium [@B38]. Thus choline may be superior to FDG in detecting coronary plaques.

2.2 Membrane markers of inflammatory cells {#Section2.2}
------------------------------------------

### 2.2.1 Translocator protein (TSPO) {#Section2.2.1}

Formerly known as peripheral benzodiazepine receptor (PBR), the 18 kDa translocator protein is located on the outer mitochondrial membrane and can bind with cholesterol and various classes of drug ligands. TSPO is ubiquitously expressed in peripheral tissues but is only minimally expressed in the healthy human brain. Previous studies found high TSPO expression in macrophages, neutrophils, lymphocytes [@B39]-[@B41], activated microglia, and astrocytes [@B42]-[@B46]. Microglia have been found to contribute to neuroinflammation in many types of central nervous system (CNS) disorders, such as stroke, multiple sclerosis (MS) [@B45], Alzheimer\'s disease (AD) [@B47], Parkinson\'s disease (PD) [@B48], amyotrophic lateral sclerosis (ALS) [@B49], and epilepsy [@B50]. Therefore, TPSO expressed on microglial cells in CNS emerges as a promising target for PET imaging of neuroinflammation. The most studied PET tracers binding to TPSO are ^11^C or ^18^F-labeled isoquinoline carboxamide PK11195 (1-(2-chlorophenyl)-*N*-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide) [@B40], [@B43] and more recently ^11^C-PBR28 (*N*-(2-\[^11^C\]methoxybenzyl)-*N*-(4-phenoxypyridin-3-yl)acetamide) [@B42], [@B51]. Syntheses of these tracers are now mostly automated and are efficient, which guarantees the future application in the clinic. In preclinical studies, for example, Yui *et al.* [@B52] used TSPO radioligands ^18^F-FEAC (*N*-benzyl-*N*-ethyl-2-\[7,8-dihydro-7-(2-^18^F-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl\]acetamide) and ^18^F-FEDAC (*N*-benzyl-*N*-methyl-2-\[7,8-dihydro-7-(2-^18^F-fluoroethyl)-8-oxo-2-phenyl-9*H*-purin-9-yl\]acetamide) in a rat brain ischemia model and found both tracers could accumulate in the infarct areas, and the uptake could be inhibited by pretreatment with TSPO ligands PK11195 or AC-5216 (*N*-benzyl-*N*-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9*H*-purin-9-yl)acetamide) **(Figure [2](#F2){ref-type="fig"})**. In an AD model, Maeda *et al.* [@B53] found elevated TSPO levels in tau-rich hippocampus and entorhinal cortex region of the brain by ^11^C-AC-5216 microPET, and there was a constant increase of tracer uptake in the brain region with the progression of AD. In a clinical study, Gulyás *et al.* used ^11^C-vinpocetine (ethyl apovincaminate) to evaluate the TSPO levels in the brains of stroke patients and found different uptake patterns in ischemic cores and peri-infarct zone over time [@B54].

PET imaging using TSPO as an inflammation biomarker has also been reported for atherosclerosis detection with promising results [@B39], [@B40], [@B55], [@B56]. Using autoradiography, Bird and colleagues [@B39] found both^3^H-DAA1106 ((N-5-fluoro-2-phenoxyphenyl)-N-(2,5-dimethoxybenzyl)acetamide) and ^3^H-(R)-PK11195 have the potential to quantify the macrophage content in human atherosclerotic plaques obtained from six patients. More recently, Gaemperl *et al.* [@B40] successfully applied ^11^C-PK11195 to image intraplaque inflammation in carotid atherosclerosis in 36 patients with carotid stenosis and found a significant correlation between ^11^C-PK11195 uptake ratio and autoradiographic measurement of TSPO binding sites **(Figure [3](#F3){ref-type="fig"}).**

TSPO PET has also been used to image inflamed lung and liver diseases. In normal lungs, TPSO is expressed in bronchial, bronchiole epithelium, and submucosal glands in intrapulmonary bronchi. In a lipopolysaccharide induced infectious lung inflammation model, PET imaging using TSPO radio-ligands ^18^F-FEDAC, ^11^C-(R)- PK11195 [@B41], and ^123^I-(R)-PK11195 [@B57] all showed significant lung lesion uptake, mainly from activated neutrophils and macrophages. Due to its higher lesion accumulation, ^18^F-FEDAC was claimed to be superior to ^11^C-(R)-PK11195. In a mouse model of non-alcoholic fatty liver disease (NAFLD), Xie *et al.* confirmed from autoradiography and histopathology that ^18^F-FEDAC uptake in NAFLD was mainly from injured hepatocytes and CD11b^+^ macrophages/activated lymphocytes located in the necroinflammatory loci [@B58], suggesting that inflammation may also contribute to NAFLD process, and ^18^F-FEDAC may be a potential tracer for NAFLD imaging.

### 2.2.2 Somatostatin Receptor {#Section2.2.2}

Somatostatin receptor (SSTR) has been investigated as a target for neuroendocrine tumor imaging. SPECT imaging of SSTR expression in neuroendocrine tumors has been well-established for lesion detection and therapeutic monitoring [@B59]-[@B62]. Since a high level of SSTR expression was found on activated lymphocytes and macrophages [@B63], this receptor has the potential to be used as a new target for inflammation imaging. Compared with tumor imaging, only limited studies have reported using PET tracers to target SSTR in inflammatory disorders or diseases with mild/intense inflammatory infiltration, including atherosclerotic inflammation [@B11], [@B64], inflamed pulmonary fibrosis [@B65], carcinoids, and inflammatory myofibroblastic tumors [@B66].

TATE (Tyr^3^-octreotate) and TOC (Tyr^3^-octreotide) are analogues of octreotide that bind to the somatostatin type 2 receptor (SSTR-2). 1,4,7,10-Tetraazacyclododecane-N,N\',N\",N\"\'-tetraacetic acid (DOTA) conjugation of these peptides allows for stable chelation to a variety of radiometals such as ^111^In, ^177^Lu, ^90^Y, ^68^Ga and ^64^Cu [@B67]-[@B69]. In atherosclerosis imaging, clear plaque uptake of ^68^Ga-DOTA-TATE or ^68^Ga-DOTA-TOC in carotid arteries was found, and the uptake has strong association with known risk factors of cardiovascular disease. Due to the much lower uptakes in myocardium, these tracers provided clearer and more consistent detection of macrophage accumulation than FDG in coronary arteries plaques [@B70], [@B71].

### 2.2.3 Type 2 Cannabinoid Receptor (CB~2~R) {#Section2.2.3}

There are at least two subtypes of CBRs in the endocannabinoid system. CB~1~R is involved in the immune system and mainly expressed in the CNS. CB~2~R is expressed at a much lower level in the normal brain tissue compared to CB~1~R. Under pathological conditions, especially immune-mediated pathologies, up-regulation of CB~2~R is found on activated microglia, the resident immune cells in the CNS [@B72]. Three major groups of CB~2~R ligands can be labeled with radioisotopes for PET, including pyrazole derivatives, indole derivatives, and quinoline derivatives [@B73]. For ^11^C-labeling of pyrazole derivatives, a boron precursor was first synthesized and later reacted with ^11^C-methyl iodide via a Suzuki coupling [@B74]. Indole derivatives such as GW405833 (1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-3-\[2-(4-morpholinyl)ethyl\]-1*H*-indole) are usually labeled with ^18^F by alkylation of the phenol precursor with 1-bromo-2-^18^F-fluoroethane [@B75]. Labeling the quinoline derivatives was readily achieved by methylating the precursor 7-methoxy-2-oxo-6-pentyloxy-1,2-dihydroquinoline-3-carboxylic acid with methyl triflate [@B73]. The first *in vivo* PET of brain CB~2~R was performed in 2010 by Horti and his group [@B76]. Mice with lipopolysaccharide induced neuroinflammation showed a significant increase in ^11^C-A-836339 uptake in all brain regions. The uptake could be blocked by a CB~2~R selective ligand, indicating the specificity of the tracer accumulation. In the same study, brain uptake of ^11^C-A-836339 (2,2,3,3-tetramethylcyclopropanecarboxylic acid (3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene)amide) uptake in AD mice was blocked only in regions with high Aβ amyloid deposition. In another imaging study, Even *et al.* used two tracers, ^11^C-Sch 225336 (N-\[(1s)-1-\[4-\[\[4-methoxy-2-\[(4-\[^11^C\]methoxyphenyl)sulfonyl)-phenyl\]sulfonyl\] phenyl\]ethyl\]methanesulfonamide\] and ^18^F-FE-GW405833, and found intense tracer accumulation in the brain of a rat model with hCB~2~R overexpression in the right striatum [@B75], [@B77]. Vandeputte *et al*. [@B78] imaged brain CB~2~R based on a reporter gene system, in which ^11^C-GW405833 clearly accumulated in the brain region with pre-injection of adeno-associated virus (AAV) vectors encoding hCB~2~R. These promising results on CB~2~R targeted PET imaging warrant further applications in a wide range of neuroinflammatory diseases and evaluation of the therapeutic value of novel CB~2~R-related drugs. However, the exact role of CB~2~R in CNS still remains to be fully elucidated, and more *in vivo* studies using relevant disease models should be conducted to get a better understanding.

### 2.2.4. Other membrane markers on inflammatory cells {#Section2.2.4}

Formyl peptide receptor (FPR) is a type of G-protein coupled receptor expressed on neutrophils, responsible for the leukocyte migration cascade in the inflammation process. Using FPR-specific ligand cFLFLFK, neutrophil infiltration in the inflammatory foci could be visualized with various imaging modalities, including MRI [@B79], optical imaging [@B80], SPECT [@B81] and PET [@B82], [@B83]. PET, using cFLFLFK-PEG-^64^Cu, could visualize inflammatory foci within the lung in an animal model of lung inflammation induced by *Klebsiella pneumonia*[@B82]. Moreover, B lymphocyte CD20 antigen imaging has been utilized to visualize synovial membrane in patients with rheumatoid arthritis [@B84]. Rituximab, an anti-CD20 monoclonal antibody, was radiolabeled with ^124^I for PET/CT imaging in six patients with rheumatoid arthritis. ^124^I-rituximab showed increased uptake in most clinically symptomatic joints, indicating the infiltration of B lymphocytes.

2.3. Inflammatory cytokines {#Section2.3}
---------------------------

### 2.3.1. COX {#Section2.3.1}

Cyclooxygenase (COX), also known as prostaglandin H, is an enzyme responsible for the conversion of arachidonic acid into prostaglandins. COX is the target of non-steroidal anti-inflammatory drugs (NSAIDs) [@B85] . In addition, COX is an integral membrane glycoprotein which can be induced by acute and chronic inflammatory stimulations. Thus far, three COX subtypes (COX-1, 2, and 3) have been identified. Among them, the inducible isoform COX-2 plays a pivotal role in cancer, cardiac/cerebral ischemia, Alzheimer\'s/Parkinson\'s disease, and response to inflammatory stimuli, especially neuroinflammation [@B86], [@B87]. Celecoxib (4-(5-*p*-tolyl-3-trifluoromethylpyrazol-1-yl)benzenesulfonamide) is broadly used as a selective COX-2 inhibitor to treat inflammatory diseases. Imaging tracers have also been developed using celecoxib and some other COX inhibitors by radiolabeling them with either^18^F or ^11^C. Reported PET tracers include ^18^F-desbromo-Dup-697 (2-(4-^18^F-fluorophenyl)-3-\[4-(methylsul-fonyl)phenyl\]thiophene) [@B88], ^18^F-SC58125 (1-\[4-(methylsulfonyl)phenyl\]-5-(4-^18^F-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole) [@B89], ^11^C-celecoxib [@B90], and ^11^C-rofecoxib (4-(4-^11^C-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one) [@B91]. They have been used to image neuroinflammations [@B91]-[@B93], tumors [@B94]-[@B96], or experimental skin inflammation [@B96]. However, most of the tracers showed unsatisfactory *ex vivo* or *in vivo* properties due to either non-specific bindings or low sensitivity in inflammatory foci, or both. Recently, Uddin *et al*. [@B96] reported an ^18^F-labeled celecoxib derivative in a rat skin model of inflammation. This derivative featured higher COX-2 inhibitory activity than celecoxib but much less defluorination rate than other ^18^F-based agents. From microPET/CT imaging, they found significant tracer uptake in the inflamed paw induced by carrageenan, which could be inhibited by celecoxib pretreatment, indicating the specificity of the tracer (**Figure [4](#F4){ref-type="fig"}**).

### 2.3.2 MMP {#Section2.3.2}

Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent metalloproteases, which can degrade protein components of the extracellular matrix (ECM) [@B97]-[@B100]. MMPs and its inhibitors, MMPIs, control the balance of extracellular proteolysis, while increased MMPs activity is considered critical in many pathological processes including cancer, atherosclerosis, and some other inflammatory conditions. Therefore, *in vivo* imaging of MMP activity would be useful to detect MMPs in these disorders. The activity of MMPs has been visualized by various probes using optical imaging, which has been summarized in several previously published review articles [@B101], [@B102]. Quite a few MMPIs have been successfully radiolabeled as imaging tracers, mainly for breast cancer detection [@B103]. ^99m^Tc and ^123^I coupled SPECT tracers targeting MMP have been broadly applied in vascular inflammation [@B104], [@B105] as well as tumor imaging. Several PET tracers have been reported, such as ^64^Cu-DOTA-CTTHWGFTLC [@B106], ^18^F-CGS27023A ((R)-2-(N-((6-^18^F-fluoropyridin-3-yl)methyl)-4-methoxyphenyl-sulphonamido)-*N*-hydroxy-3-methylbutanamide) derivative [@B49], and ^11^C-labelled counterpart of CGS27023A [@B107], for tumor imaging. In a PET study of vessel inflammation, Hartung *et al.* [@B108] used ^124^I-HO-MIP (CGS 27023A) in ApoE^-/-^ mice after carotid ligation following a high-cholesterol diet. Intense tracer uptake in the carotid lesion was detected from microPET images, indicating increased local MMP activity **(Figure [5](#F5){ref-type="fig"}).**The imaging results were in accordance with histology and immunohistochemistry for MMP expression. In another study [@B103], ^18^F-MMPI was used in ApoE^-/-^ mice on a high-cholesterol diet. *Ex vivo* PET/CT shows MMP-positive plaques in the inner curvature of the aorta.

### 2.3.3 IL-2 {#Section2.3.3}

Interleukin (IL)-2 is a small single-chain glycoprotein (15.5 kDa) of 133 amino acids synthesized and secreted by activated T lymphocytes, especially CD4^+^ and CD8^+^ Th1 lymphocytes. T lymphocyte activation is seen in many types of inflammatory diseases, such as inflammatory degenerative diseases, graft rejection, tumor inflammation, organ-specific autoimmune diseases, and adipose inflammatory insulin resistance [@B109]. IL-2 binds with high affinity to the cell membrane IL-2 receptor, which is mainly expressed on the cell surface of activated T lymphocytes. PET imaging of activated T lymphocytes by radiolabeled IL-2 therefore provides an *in vivo*, dynamic approach in studying the immune-cell infiltration in these inflammatory diseases. Previously, ^123^I and ^99m^Tc labeled IL-2 have been used in many chronic inflammatory diseases, such as autoimmune diseases [@B110], coeliac disease [@B111], and vulnerable atherosclerotic plaques [@B112] *via* SPECT imaging. However, routine application of this technique was limited because the labeling procedures is complex and the spatial resolution of SPECT is not high enough. Recently, Gialleonardo *et al.* reported the labeling of IL-2 with *N*-succinimidyl 4-^18^F-fluorobenzoate (^18^F-SFB) for the synthesis of ^18^F-FB-IL-2 to detect activated T lymphocytes in inflammation [@B113]. In one of their studies, SCID mice were inoculated with phytohemagglutinin-activated human peripheral blood mononuclear cells (hPBMc) in Matrigel on the right flank while only Matrigel was injected as control on the left. At 60-90 min after cell inoculation, PET imaging found that ^18^F-FB-IL-2 could detect the implanted hPBMc on the right flank. However, the control side also showed tracer uptake, mainly around the Matrigel site. The authors claimed that it was probably due to the migration of hPBMc from right side to left as a result of Matrigel induced inflammation. They also performed a dynamic PET study in Wistar rats with xenografted hPBMC [@B114]. Tracer accumulation to activated T cells was clearly observed and the kinetics of ^18^F-FB-IL-2 in an inflammatory lesion could be described by Logan graphical analysis and compartment modeling. These pilot studies suggest that ^18^F-FB-IL-2 is stable, biologically active, and allows for *in vivo* detection of activated T lymphocytes.

### 2.3.4 TNF-α {#Section2.3.4}

Tumor necrosis factor-α (TNF-α) is a cytokine that can contribute to cell apoptosis and organ dysfunction [@B115]. In the early phase of inflammation, TNF-α increases the transport of white blood cells to the inflammation sites. In the late phase, TNF-α level is lowered and can cause the apoptosis of inflammatory cells to terminate further unnecessary inflammation. Many studies show that TNF-α is important in acute immune response to infection, injury, autoimmune and chronic inflammatory disorders such as rheumatoid arthritis [@B15] and psoriasis [@B14]. Previously, our group used a PET tracer ^64^Cu-DOTA-etanercept, to image acute inflammatory process induced by 12-O-tetradecanoylphorbol-13-acetate (tetradecanoyl phorbol acetate, TPA) [@B116]. MicroPET imaging showed high ^64^Cu-DOTA-etanercept uptake in the inflamed ear only during the early acute inflammatory phase but not the chronic inflammation phase, indicating that TNF-α contributes to the onset of acute inflammation (**Figure [6](#F6){ref-type="fig"}, left**). This imaging trend was confirmed by *ex vivo* enzyme-linked immunosorbent assay (ELISA) assay of TNF-α levels in the inflamed ears. Gao *et al.* synthesized ^11^C-labeled tricyclic Nec-3 necroptosis inhibitor 3,3a,4,5-tetrahydro-2H-benz\[*g*\]indazoles as a potential PET tracer for imaging TNF-α, but without *in vivo* evaluation [@B117].

2.4 Targets on inflammation related vessels {#Section2.4}
-------------------------------------------

### 2.4.1 Integrin receptor {#Section2.4.1}

Integrin α~v~β~3~, a cell adhesion molecule, is overexpressed in various cancer cells [@B118], endothelial cells of neovessels [@B119], and also in some inflammatory cells such as macrophages [@B120], [@B121]. The study of integrin α~v~β~3~ in cancers and tumor related angiogenesis has been extensively investigated in the past two decades [@B122]-[@B124]. RGD peptides containing the three amino acid sequence Arg-Gly-Asp, are αvβ3 specific ligands. Radiolabeled RGD peptides have been successfully tested in the clinic [@B125], complementing conventional FDG imaging. Recently, some chronic inflammatory conditions with inflammatory angiogenesis, such as inflammatory bowel disease [@B126] and rheumatoid arthritis [@B127], also showed the participation of integrin αvβ3 in the inflammatory neovessels in disease etiology and progression. Therefore, integrin αvβ3 emerges as a target for inflammation therapy as well as molecular imaging. Actually, studies on αvβ3 targeted treatment have shown success in several inflammatory diseases [@B127], [@B128]. Several PET studies of inflammatory processes using radiolabeled RGD peptides have also been reported. Pichler *et al.* [@B129] used ^125^I-gluco-RGD and ^18^F-gluco-RGD to study 2,4,6-trinitrochlorobenzene (TNCB) induced delayed-type hypersensitivity reaction (DTHR) model of inflammation and found chronic but not acute inflammatory ear had intensive tracer uptake, which could be further blocked by pre-injection of cold RGD. The imaging result was verified by histology and immunohistochemistry of αvβ3 expression in the inflammatory foci. These findings echo what we observed in acute and chronic ear inflammation models using a different αvβ3 radioligand, ^64^Cu-DOTA-E\[c(RGDyK)\]~2~}~2~ [@B116] (**Figure [6](#F6){ref-type="fig"}, right**). Both studies suggest that radiolabeled RGD peptides can reflect the angiogenesis during chronic inflammatory process.

In addition to imaging inflammatory angiogenesis, using RGD peptide in atherosclerosis imaging also came with positive results. Laitinen *et al.* [@B130] found ^18^F-Galacto-RGD accumulation in atherosclerotic lesions of mouse aorta by small animal PET/CT, and the high tracer uptake was associated with macrophage density revealed by histology study. In another study using hypercholesterolemic LDLR^-/-^ApoB^100/100^ mice, the same group investigated the effect of lipid-lowering diet on plaque formation. They found that ^18^F-galacto-RGD uptake in the aorta from regular food group is significantly lower than that from the high-fat diet group, indicating lipid-lowering diet could decrease the formation of atherosclerosis. Overexpression of α~v~ and β~3~ integrins on macrophages in the aorta was confirmed by flow cytometry [@B131]. Still others used ^68^Ga-DOTA-RGD to image plaques *ex vivo* to measure the degree of inflammation and the vulnerability of atherosclerotic plaques [@B132]. Autoradiography showed significantly higher uptake of ^68^Ga-DOTA-RGD in plaques as compared to the healthy vessel wall and adventitia. However, there was no significant difference in aorta tracer uptake compared to control mice, which was probably due to the tissues around the healthy vessel wall, and the overall low uptake of the tracer in therosclerotic plaques. Therefore, further studies are needed to determine the validity of RGD peptide tracers to image arterial plaques in human.

### 2.4.2 VAP-1 {#Section2.4.2}

Vascular adhesion protein 1 (VAP-1) is an endothelial adhesion protein stored in intracellular granules within endothelial cells. The expression of VAP-1 is quite low on the endothelial surface of normal tissues. Upon stimulation, VAP-1 is translocated onto the luminal surface of endothelial cells at sites of inflammation, causing the migration of leukocytes, especially CD8^+^ T lymphocytes, from the blood into the non-lymphoid inflammatory foci [@B133]. VAP-1 is, therefore, a promising target for both anti-inflammation therapy and molecular imaging of inflammation. A number of studies using radiolabeled synthetic peptides have been attempted to image VAP-1 expression [@B24], [@B134]-[@B137]. These ligands were either designed by molecular modeling based on the crystal structure of human VAP-1 or selected from phage display libraries and were labeled with ^68^Ga to form ^68^Ga-DOTA-Siglec-9 [@B136], ^68^Ga-DOTAVAP-P1 [@B24], [@B137], ^68^Ga-DOTAVAP-PEG-P1 [@B134], or ^68^Ga-DOTAVAP-PEG-P2 [@B135]. These VAP-1 targeted PET tracers have been tested in sterile/infectious inflammatory and tumor-bearing animal models. In one study, ^68^Ga-DOTAVAP-P1 was compared with ^18^F-FDG to differentiate turpentine oil induced muscular inflammation and human BxPC3 xenografted tumors [@B24]. PET with ^68^Ga-DOTAVAP-P1 showed intensive inflammatory foci uptake, concordant with the high VAP-1 expression examined by *ex vivo* studies. However, ^68^Ga-DOTAVAP-P1 had very low uptake in BxPC3 tumors (**Figure [7](#F7){ref-type="fig"}**), suggesting the ability of this tracer to tell inflammation from tumor. In contrast, FDG showed high uptake in both inflammation foci and tumors, unable to discriminate one from the other. ^68^Ga-DOTAVAP-P1 has also been used to image osteomyelitic bones [@B138] and differentiate osteomyelitic bones from inflammation in healing bones [@B137]. In the differentiation study in particular, rat model of healing cortical bone defects (representing the sterile inflammation process of bone healing) and bone osteomyelitis were compared using ^68^Ga-DOTAVAP-P1 PET. At day 7 after operation, the sterile inflammation in healing cortical bone defect showed a significant decrease in tracer uptake, while osteomyelitis uptake of ^68^Ga-DOTAVAP-P1 remained high. This study showed the potential of ^68^Ga-DOTAVAP-P1 to differentiate bacterial infection from nonbacterial inflammation.

### 2.4.3 VCAM-1 {#Section2.4.3}

Vascular cell adhesion molecule (VCAM)-1 is one member of the immunoglobulin superfamily of endothelial adhesion molecules. It plays an important role in all stages of atherosclerotic plaque [@B139], [@B140]. It is expressed on activated endothelium and can induce the adhesion of macrophages at the early stage of plaque formation. A linear peptide affinity ligand, VHPKQHR, was identified using *in vivo* phage display in apolipoprotein E-deficient mice. This sequence is homologous to very late antigen-4, a known ligand for VCAM-1 [@B141]. A multivalent PET imaging agent (^18^F-4V) has been developed based on this peptide sequence and applied to evaluate expression of VCAM-1. In (ApoE)^-/-^ mice with atherosclerotic plaques located in the aortic root, PET images showed strong focal signal in the aortic root. Consistent with the imaging results, a high level of VCAM-1 mRNA was confirmed in the aortic sections. Also in this study, PET imaging using ^18^F-4V was used for other cardiovascular disorders, such as myocardial infarction and transplant rejection with possible VCAM-1-mediated monocyte recruitment. Images showed ^18^F-4V uptake in the infarcted left ventricular wall in the MI model mice and in the cardiac allograft models; the inflamed myocardium also showed high tracer uptake after transplanted cardiac allografts underwent rejection.

### 2.4.4 Vessel permeability {#Section2.4.4}

In normal conditions, vascular integrity is important in maintaining the homeostasis of the internal environment. Upon stimulation by various stimuli, as in acute inflammatory process, local vessel permeability is remarkably increased due to the release of many cytokines, chemokines, and leukotrienes by resident inflammatory cells and endothelial cells. This is important for self-defense by allowing immune cells such as neutrophils and macrophages to infiltrate into inflammatory foci. Therefore, either in sterile or infectious inflammation, increased vessel permeability could be utilized as a "biomarker" for inflammation imaging. Gallium ion has traditionally been used to image inflammation with gamma cameras. The accumulation of ^67^Ga in inflammation foci can be explained either by binding to transferrin then diffusing into sites of inflammation via increased vascular permeability, or by binding to local lactoferrin produced by leucocytes, or siderophores produced by infecting micro-organisms [@B142]. However, the disadvantages of ^67^Ga limit its wide-spread applicationz, such as high cost, long half-life (3.26 d) and poor imaging quality due to its wide spectrum of gamma rays emitted. ^68^Ga has the same chemical characteristics as ^67^Ga, but with easier production procedure, short half-life (68 min) and positron-emitting property, therefore making it a better alternative for inflammation PET imaging. In fact, ^68^Ga is now in clinical trials for imaging infectious bone [@B143] and non-infectious bone defect healing process [@B144]. In these studies, infectious inflammatory bones showed high uptake of ^68^Ga or ^68^Ga-citrate, while animal models of bone defect without infection did not show very significant local^68^Ga uptake. Although local vessel permeability is increased under both conditions, the authors suggested that this might due to the binding of ^68^Ga to the siderophores produced by micro-organisms which did not exist in the sterile inflammation. Therefore infectious bone had higher ^68^Ga uptake than the non-infectious bone defect. Consequently, it is reasonable to assume that ^68^Ga PET will be more valuable than conventional ^18^F-FDG imaging in lowering the odds of false-positive findings in post-surgical and post-traumatic bone healing [@B144].

^68^Ga has also been used to image atherosclerotic inflammation in animal models [@B12]. Intensive atherosclerosis uptake of ^68^Ga was observed in this study. The reasons for the accumulation in inflamed plaques, as the authors claimed, might be due to locally increased vessel permeability, competitive binding to the Ca^2+^ and Mg^2+^ in calcified areas or binding to the circulating transferrin and to the transferrin receptors at the site of atherosclerotic artery binding sites.

3. Evaluation of inflammatory diseases using PET {#Section3}
================================================

An increasing number of diseases have recently been found to be inflammation related, such as atherosclerosis [@B145], neurodegenerative disorders [@B146], and malignant tumors [@B147]. Non-invasive PET imaging has the potential to help figure out the mechanism of inflammatory disease processes, discover potential targeted therapeutics, and establish new diagnostic standards.

3.1 Cardiovascular inflammation: focusing on atherosclerosis {#Section3.1}
------------------------------------------------------------

As an inflammatory disease, the onset, progression, and destabilization of atherosclerosis involves multi-participants within the immune response, including activation of endothelial cells, infiltration of various cells, release of inflammatory cytokines, and macrophage apoptosis. Due to the high morbidity and mortality rates of atherosclerosis, early detection and full characterization of atherosclerosis is of extreme necessity. So far, ^18^F-FDG is the most extensively used probe for atherosclerosis imaging [@B9], [@B13], [@B148], [@B149] **(Table [1](#T1){ref-type="table"})**. Many preclinical and clinical studies have established the correlation not only between local FDG uptake and plaque macrophage density but also between high metabolic activities of macrophages within plaques and cardiovascular risk factors. However, the partial volume effect, high physiology uptake of ^18^F-FDG in the myocardium or brain, and motion artifacts from cardiac movement all make visualization of small atherosclerotic plaques in these areas rather cumbersome. In fact, besides high glucose metabolism, many inflammation biomarkers have been evaluated for atherosclerosis PET imaging, including the aforementioned choline metabolism, TSPO, SSTR, VAP-1, MMPs, integrin receptors, and VCAM-1. Some of the PET probes, such as radio-labeled PK11195 (binding to TPSO), choline (targeting to the phosphatidylcholine catabolism of macrophages and monocytes), TATE/TOC (binding to SSTR), are superior to conventional ^18^F-FDG in their low myocardium biodistribution. Consequently, the images achieved high target-to-background ratio, facilitating the analysis of small coronary plaques. In addition, PET imaging of MMPs could assess the plaque-promoting activity of macrophages rather than their density in vulnerable plaques, and integrin receptor targeted imaging could detect CD68-positive macrophages in the vulnerable plaques [@B120]. PET imaging of these biomarkers, together with other conventional angiography, opens up the opportunity for better diagnosis and prognosis of atherosclerosis.

3.2 Neuroinflammation {#Section3.2}
---------------------

Recently, accumulating evidences have revealed that many chronic neuroinflammatory diseases are caused by activated microglia in the CNS [@B150]. As the resident immune cells in the CNS, microglial cells are activated in the acute neuroinflammation phase and protect brain tissue from further injury through migration, proliferation, and production of neurotoxic factors. However in chronic neuroinflammation, microglia activation causes long-term cerebral damage by inducing autoimmune reaction. The activation of microglia is observed in various CNS diseases such as stroke, multiple sclerosis, Alzheimer\'s disease, and Parkinson\'s disease [@B151]. Several known neuroinflammation related targets include TSPO, CB~2~R, and COX-2. Among them, TSPO is the most popular target for PET imaging which has already undergone clinical application, while CB~2~R and COX-2 are still in the preliminary stage as imaging targets (**Table [3](#T3){ref-type="table"}**).

As for the clinical translation, although some limitations do exist, TPSO targeted PET imaging of neuroinflammatory disease has provided some helpful information in disease diagnosis and prognosis. For example, in AD patients, TPSO PET enabled the discovery of the relationship between Aβ accumulation and microglia activation during disease process [@B152] and can detect an age related increase in microglia activation in normal human brains and in AD progression [@B153]. However, based on current research, no definite conclusion can be drawn between the results of amyloid plaque imaging using ^11^C-PIB and inflammation imaging targeting TPSO [@B53], [@B154], [@B155]. Microglia activation was found to be a potential driving force in the development of Parkinson\'s disease with dementia (PDD) and could be detected via TPSO PET at the early phase in PD patients [@B156]. In stroke, TSPO PET imaging was able to find the temporal dynamics of microglia activation in patients, which was correlated with clinical outcome [@B157]. In traumatic brain injury (TBI), the imaging of microglia via TSPO was found to be present up to 17 years after TBI, indicating the possible benefit of long-term interventions for post-TBI patients [@B158]. However, some discrepancies exist among different studies, and this might be due to the lack of standardized analysis of imaging results and certain limitations of radiotracer for PET neuroinflammation imaging, such as low binding affinity and low target-to-background ratio [@B159]. Therefore, the development of new tracers with better imaging properties and the improvement in quantitative data analysis should be of great importance for PET guided neuroinflammation imaging in the future.

3.3 Tumor related inflammation {#Section3.3}
------------------------------

Inflammation contributes to a tumor\'s immune escape phenomenon, creating a proper environment for neoplastic onset and continued growth. In fact, inflammatory cells and mediators are present in the microenvironment of virtually all tumors that are not epidemiologically related to inflammation [@B166]. Recently, tumor-associated macrophages (TAMs) or tumor-infiltrating macrophages (TIMs) have been intensively investigated as a target for imaging and therapy [@B167]. TAMs enhance tumor cell migration and invasion through their secretion of chemotactic and chemokinetic factors [@B168]. Depletion of TAMs improved the effect of chemotherapy in some cancer models [@B169]. Therefore, TAMs targeted imaging would have great value providing guidance for macrophage targeted cancer therapy and patient stratification for personalized treatment. Various molecular imaging techniques have been applied to study TAMs, including MRI [@B170], optical imaging [@B171], PET [@B172], SPECT [@B173], and hybrid molecular imaging modality [@B174], [@B175], in which most of the imaging agents are nanomaterial based. Studies performed by Zheng *et al.* [@B176] using ^18^F-DPA-714, a TSPO specific tracer, proved that TSPO was positive in both breast cancer cells and TAMs. These results supported that TSPO expression inside tumors came from mixed cell populations, leading the way for future development of imaging and therapeutic ligands targeting TSPO on macrophages. In another study, Locke *et al*. [@B82] performed PET imaging of TAMs using mannose coated ^64^Cu liposomes and showed that the imaging agent could accumulate in TAMs in a pulmonary adenocarcinoma foci in a mouse model.

Because FDG could also accumulate in non-neoplastic cells that infiltrate neoplasms [@B167], without histological validation, it remains unclear what percentage of FDG accumulation is caused by peritumoral and intratumoral inflammation. Hence, it is a consensus in clinical setting that cancer therapy evaluation using FDG PET should be carefully conducted, especially when effective treatment can lead to massive inflammation. Consequently, many studies focused on developing more tumor cell specific PET tracers beyond FDG. Some tumor proliferation markers such as lipid precursors, amino acids, nucleosides, and receptor ligands have been tested for this purpose. For example, ^11^C-choline was developed to evaluate intracellular choline kinase activity, ^11^C-methionine (MET) to image amino acid transporter, and ^18^F-fluorothymidine (FLT) to determine thymidine kinase 1 activity [@B177]. In a preclinical study, Lee *et al.* [@B178] examined ^18^F-FET and ^18^F-FLT along with ^18^F-FDG to differentiate tumor from inflammation. They found ^18^F-FET and ^18^F-FLT selectively localized in tumor tissues but not inflammation. Similar results were also reported elsewhere [@B179], [@B180]. Clinical studies also demonstrated that ^18^F-FLT is significantly better than ^18^F-FDG as a measure of tumor proliferation and more specific than ^18^F-FDG PET for cancer staging. However, tumor uptake of ^18^F-FLT is much less than ^18^F-FDG, resulting in a significantly lower sensitivity for ^18^F-FLT PET than for ^18^F-FDG PET [@B181].

Several inflammation biomarkers may be promising in differentiating tumor from inflammation including VAP-1 and integrins. As mentioned before, the VAP-1 targeted peptidic tracer, ^68^Ga-DOTAVAP-P1, showed accumulation in inflammation foci but not as much in tumors, making it a potential inflammation-targeting tracer [@B24]. ^18^F-FPPRGD2, an integrin receptor targeting probe, was found to be superior to ^18^F-FDG in monitoring tumor response to Abraxane treatment, possibly due to less uptake in TAM [@B182]. Admittedly, it is very challenging to develop an imaging probe which can separate tumor and inflammation completely since inflammation is an inherent tumor microenvironment.

4. Conclusion and perspectives {#Section4}
==============================

The process of inflammation is involved, either directly or indirectly in various human diseases, including stroke, Alzheimer\'s disease, atherosclerosis, autoimmune diseases, and even malignant disorders. Therefore, information extracted from molecular imaging of inflammation in these disorders is definitely helpful in disease diagnosis, and prognosis, therapy response monitoring, and shedding light on understanding the nature of disease processes. So far, many inflammation related biomarkers have been identified and investigated as imaging or therapy targets, including inflammatory cell metabolism, membrane markers, cytokines, and vascular changes during inflammation. After intensive preclinical studies, some of these targets have been tested in humans. For example, FDG PET has been used to evaluate inflammation in atherosclerosis plaques, and many new tracers in proof-of-concept clinical studies showed promise in discerning inflammation from background. To evaluate neuroinflammation in AD, PD, and ischemic neural diseases, PET imaging of TSPO expression on activated microglia showed very promising results. For tumor related inflammation imaging, tumor-associated macrophages become widely explored targets. In the never-ending debate on differentiating tumor from inflammation, a variety of PET probes have been studied. However, very few of them are considered to be inflammation specific. With better understanding of the inflammatory reaction in each disease type, more sensitive and specific biomarkers will be identified, and potential new imaging probes may be developed to target these biomarkers. Moreover, multiplexed imaging with tracers targeting different biomarkers and multimodal imaging by incorporating PET with other imaging modalities will also contribute to improved visualization and quantification of the inflammatory diseases.
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![PET inflammation imaging biomarkers within the inflammatory foci.](thnov03p0448g01){#F1}

![Representative PET images and time activity curves of ^18^F-FEAC in infarcted rat brains 7 days after surgery. PET images were generated by averaging the whole 60-min scans and were overlaid on MR images. Arrows indicate infarcted areas. Shown are control rats (A and D), rats pretreated with AC-5216 (B and E), and rats pretreated with PK11195 (C and F) (Yui, 2010 [@B52]).](thnov03p0448g03){#F2}

![Computed tomography angiography (A), ^11^C-PK11195 PET (B), and PET/CT fusion (C) in a 52-year-old patient with right amaurosis fugax 2 weeks prior to the scans. The white arrows denote a focal area of ^11^C-PK11195 uptake in the carotid bifurcation (Gaemperl, 2011 [@B40]).](thnov03p0448g04){#F3}

![(A) COX-2 targeted microPET/CT imaging of mouse paw inflammation induced by carrageenan. The PET image shows that the radiotracer targeted the swollen footpad (inflamed) selectively over the contralateral footpad (control). (B) PET image of rats with paw inflammation predosed with celecoxib (Uddin, 2011 [@B96]).](thnov03p0448g05){#F4}

![Site of ligated left common carotid artery (left panel) and a corresponding whole body coronal slice (0.4 mm thick) through a left carotid lesion (right panel) 4 weeks after ligation and a high cholesterol diet in an apoE^-/-^mouse. Intense uptake of the radiolabeled broad spectrum MMP inhibitor ^124^I-HO-MPI in the left carotid lesion (arrow) 30 min after intravenous injection is visible using high-resolution small animal PET (Hartung, 2007 [@B108]).](thnov03p0448g06){#F5}

###### 

MicroPET imaging using ^64^Cu-DOTA-etanercept (left) and ^64^Cu-DOTA-RGD (right) of mouse right ear subjected to TPA challenge at various times. ^64^Cu-DOTA-etanercept showed intensive ear uptake only in acute inflammation phase, while ^64^Cu-DOTA-RGD showed chronic inflammatory ear uptake (Cao, 2007 [@B116]).
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###### 

^68^Ga-DOTAVAP-P1 (a, b) and ^18^F-FDG (c, d) PET imaging of mice with BxPC-3 tumor inoculation and turpentine induced inflammation. (a) ^68^Ga-DOTAVAP-P1 uptake is clearly seen at the site of inflammation (arrow A) but not in the muscle (arrow B) or the tumor (arrow C). (b) Time-activity curve (TAC) of ^68^Ga-DOTAVAP-P1 uptake in the inflammation site, muscle and tumor. (c) ^18^F-FDG uptake is clearly seen at the site of inflammation (arrow A) as well as the tumor (arrow C). (d) TAC of ^18^F-FDG uptake in the inflammation site, muscle, and tumor (Autio, 2010 [@B24]).
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###### 

^18^F-FDG imaging of sterile inflammatory diseases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diseases                Study type                  References                                        Tracers                                              Remarks
  ----------------------- --------------------------- ------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------
  Atherosclerotic\        Clinical                    Li, 2012 [@B11]                                   ^18^F-FDG, ^68^Ga-DOTATATE ( PET/CT)                 In patients with neuroendocrine tumors or thyroid cancer
  inflammation                                                                                                                                               

  Preclinical             Silvola, 2011 [@B12]        ^18^F-FDG, ^68^Ga (microPET/CT)                   In LDLR^-/-^ ApoB100/100 mice                        

  Clinical                Yarasheski, 2012 [@B13]     ^18^F-FDG (PET/CT)                                In HIV-infected patients                             

  Vasculitis              Clinical                    Bissonnette, 2012 [@B14]                          ^18^F-FDG (PET/CT)                                   In psoriasis patients

  Clinical                Maki-Petaja, 2012 [@B15]    ^18^F-FDG (PET/CT)                                Anti-TNF therapy, in rheumatoid arthritis patients   

  Clinical                Tegler, 2012 [@B16]         ^18^F-FDG (PET/CT)                                Aortic aneurysms                                     

  Clinical                Tezuka, 2012 [@B17]         ^18^F-FDG (PET/CT)                                Takayasu arteritis                                   

  Clinical                Sarda-Mantel, 2012 [@B18]   ^18^F-FDG, ^18^F-DPA714, ^18^F-FCH (PET)          Abdominal aneurysms                                  

  Clinical                Kim, 2010 [@B19]            ^18^F-FDG (PET/CT)                                In T2DM patients                                     

  Valvular inflammation   Clinical                    Dweck, 2012 [@B20]                                ^18^F-FDG, ^18^F-NaF (PET/CT)                        

  Arthritis               Preclinical                 Irmler, 2010 [@B21]                               ^18^F-FDG (PET/CT)                                   With etanercept therapy

  Clinical                Yamashita, 2012 [@B22]      ^18^F-FDG (PET/CT)                                Differentiation among PMR, SpA and RA                

  Skin inflammation       Preclinical                 McLarty, 2011 [@B23]                              ^18^F-FDG, ^18^F-*scyllo*-inositol (microPET)        

  Preclinical             Autio, 2010 [@B24]          ^18^F-FDG, ^68^Ga-DOTAVAP-P1 (animal/brain PET)                                                        

  Bone inflammation       Preclinical                 Brown, 2012 [@B25]                                ^18^F-FDG (microPET)                                 Differentiation with osteomyelitis

  Myocardial\             Clinical                    Lee, 2012 [@B26]                                  ^18^F-FDG (PET/MR)                                   Post-myocardial infarction
  inflammation                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**TNF**: tumor necrosis factor **T2DM**: Type 2 Diabetes Mellitus **RA**: rheumatoid arthritis **PMR**: polymyalgia rheumatic **SpA**: seronegative spondyloarthritis.

###### 

PET imaging targets for inflammation and corresponding PET probes.
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###### 

CNS diseases evaluated by PET targeting on inflammatory biomarkers.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease Type                   Imaging target       Clinical / Preclinical   Imaging modality     Tracer                                          References                    
  ------------------------------ -------------------- ------------------------ -------------------- ----------------------------------------------- ----------------------------- --
  Traumatic brain injury (TBI)   TSPO                 Preclinical, rat         Animal PET           ^18^F-DAA1106, ^11^C-verapamil, ^11^C-PK11195   Yu, 2010 [@B160]\             
                                                                                                                                                    Folkersma, 2011 [@B161]       

  TSPO                           Clinical             PET, MRI                 ^11^C-PK11195        Ramlackhansingh, 2011 [@B158]                                                 

  Cerebral ischemia              TSPO                 Preclinical, rat         PET, MRI             ^18^F-DPA-714\                                  Martin, 2010 [@B162]\         
                                                                                                    ^18^F-FEAC\                                     Yui, 2010 [@B52]              
                                                                                                    ^18^F-FEDAC                                                                   

  TSPO                           Clinical             PET, MRI                 ^11^C-vinpocetine\   Gulyás, 2012 [@B54]\                                                          
                                                                               ^11^C-Pk11195        Thiel, 2010 [@B157]                                                           

  Multiple sclerosis (MS)        TSPO                 Preclinical, rat         Animal PET           ^11^C-DAC                                       Xie, 2012 [@B163]             

  TSPO                           Clinical             PET, MRI                 ^11^C-PBR28          Oh, 2011 [@B45]                                                               

  Alzheimer\'s Disease (AD)      TSPO                 Preclinical, mouse       Animal PET           ^11^C-AC-5216\                                  Maeda, 2011 [@B53]            
                                                                                                    ^18^F-FEDAA1106                                                               

  TSPO                           Clinical             PET, MRI                 ^11^C-vinpocetine\   Gulyás, 2011 [@B153]\                                                         
                                                                               ^11^C-PK11195        Yokokura, 2011 [@B152]                                                        

  CB~2~R                         Preclinical, mouse   animal PET               ^11^C-A-836339       Horti, 2010 [@B76]                                                            

  Parkinson\'s Disease (PD)      TSPO                 Clinical                 PET, MRI             ^11^C-PK11195                                   Gerhard, 2006 [@B164]\        
                                                                                                                                                    Edison, 2012 [@B156]          

  Huntington\'s\                 TSPO                 Clinical                 PET, MRI             ^11^C-PK11195\                                  Politis, 2011 [@B165]         
  disease (HD)                                                                                      ^11^C-raclopride                                                              

  Epilepsy                       TSPO                 Clinical (one case)      PET, MRI             ^11^C-PK11195                                   Dedeurwaerdere, 2012 [@B51]   

  Brain inflammation             COX                  Preclinical, rat         Animal PET           ^11^C-ketoprofen methyl ester\                  Shukuri, 2011 [@B92]\         
                                                                                                    ^11^C-rofecoxib                                 de Vries, 2008 [@B91]         

                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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